Pandemic influenza vaccine GSK2340272A

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Influenza

Phase 2

Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)

CompletedNCT00971321

GlaxoSmithKlineInfluenza

Start: 2009-09-10End: 2010-11-24Updated: 2019-02-25

Phase 3

Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)

CompletedNCT00964158

GlaxoSmithKlineInfluenza

Start: 2009-09-10End: 2010-11-27Updated: 2018-02-19

Related Papers

Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies

Human Vaccines & Immunotherapeutics2015-07-158 citations